Karenitecin
Information
- Drug Name
- Karenitecin
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Karenitecin: topoisomerase I inhibitor. The same a... | HDAC9 | HDAC9 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00010218 | Completed | Phase 2 | Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer | April 2001 | January 2006 |
| NCT00014521 | Completed | Phase 1 | Karenitecin in Treating Patients With Recurrent Malignant Glioma | January 2002 | |
| NCT00477282 | Completed | Phase 3 | Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer | August 2007 | June 2013 |
| NCT00358319 | Terminated | Phase 1/Phase 2 | Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma | March 2005 | April 2007 |